Pembrolizumab versus Ipilimumab in Advanced Melanoma

20155,785 citationsJournal Articlebronze Open Access

Authors

Caroline Robert · Université Paris-Sud

Jacob Schachter · Sheba Medical Center

Georgina V. Long · Mater Hospital

Ana Arance · Target (United States)

Jean‐Jacques Grob · Hôpital de la Timone

Laurent Mortier · Centre Hospitalier Universitaire de Lille

Adil Daud ·

Abstract

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).

Topics & Keywords

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Melanoma and MAPK Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 26, pp. 2521-2532

DOI: 10.1056/nejmoa1503093

Field-Weighted Citation Impact: 322.79